Trastuzumab deruxtecan (T-DXd) vs physician's choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior...

Authors :: Curigliano, Giuseppe
Hu, Xichun
Dent, Rebecca Alexandra
Yonemori, Kan
Barrios Sr., Carlos H.
O'Shaughnessy, Joyce
Wildiers, Hans
Zhang, Qingyuan
Im, Seock-Ah
Saura, Cristina
Biganzoli, Laura
Sohn, Joohyuk
Levy, Christelle
Jacot, William
Begbie, Natasha
Ke, Jun
Patel, Gargi Surendra
Bardia, Aditya
Source :: Journal of Clinical Oncology; 2024 Supplement 17, Vol. 42, pLBA1000-LBA1000, 83p
Publication Year :: 2024

Full Text Access

Tools